Introduction

Neuroblastoma is one of the most common type of cancer in children. The cancer is triggered as an outcome of embryonal malignancy in sympathetic nervous system radically arising from the neuroblasts. The cancer develops in the nerve tissues of adrenal, spinal cord or chest.

The National Institute of Health (NIH) in U.S. and Orphanet in Europe classify neuroblastoma as “rare disease”. The cancer is more common in children’s below age of five, showing peek prevalence ration in 2-3 years of age group.

As per the America Cancer Society, over 7.2% of the all cancer cases in 0 to 14 years of age group. Data also signifies that the neuroblastoma similarly affects both sexes equally across the world. Growing number of tests to help to treat and manage individual health conditions is anticipated drive the market for neuroblastoma over the study period.

A cancer study published in Journal of Clinical Oncology advocates that number of Native American and black neuroblastoma patient’s pool have a high risk of affecting. Considering regional parity in prevalence the global neuroblastoma market for is estimated to generate adequate revenues.

The emerging demand for neuroblastoma treatment is largely arising from the increased awareness of the people towards cancer care. The major factor driving the growth of neuroblastoma market is increasing prevalence of cancer and growing awareness about neuroblastoma radiation therapy.

The continuously growing adoption of targeted drug therapy and advancement in immunotherapy is driving the demand for neuroblastoma market. Moreover, the growing research on irinotecan, temozolomide, and topotecan are also increases the likelihood for adopting novel Neuroblastoma therapeutics techniques subsequently increasing demand for Neuroblastoma treatment.

The rapidly developing radiotherapy care and inventions are the key factor in early detection of genetic disorders. New and improved clinical therapies are emerging as a preferred choice of treatment for neuroblastoma utilizing ultrasound to targeted deep areas of the brain and resulting in focused ultrasound ablation for the treatment of neuroblastoma.

However, stringent regulatory guidelines for drugs used in Neuroblastoma treatment combined with limited awareness about Neuroblastoma cancer testing is expected to restrain growth of the Neuroblastoma market.